Navigation Links
Appeal of Lawsuit by Former Officer Dismissed; Request for Sanctions Granted
Date:2/24/2010

ORLANDO, Fla., Feb. 24 /PRNewswire-FirstCall/ -- GeneLink, Inc. (OTC Bulletin Board: GNLK), a leading consumer genomics biotech company, is pleased to report that the Superior Court of Pennsylvania has dismissed the appeal filed by the Company's former CEO and President, John DePhillipo, and his wife against the Company, its subsidiary GeneWize Life Sciences, Inc., and several of the Company's officers, directors and advisors.  The Court also awarded sanctions in favor of the GeneLink Parties against the DePhillipos and their counsel, with the amount of such sanctions to be determined in the future by the Court of Common Pleas of Pennsylvania, Philadelphia County.  

The DePhillipos' appeal arose from the May 5, 2009 Order and Opinion of the Court of Common Pleas of Pennsylvania, Philadelphia County wherein that Court dismissed the DePhillipos' claims as unviable.  

About GeneLink BioSciences, Inc.:

GeneLink Biosciences is a genomics, biotechnology, and wellness company engaged in genetic profile development, product development, business development and support services for its subsidiaries and distribution partners.  GeneLink's patented and patent pending technologies include proprietary genetic assessments and products linked to personalized health, beauty and wellness applications. For additional information, please visit www.genelinkbio.com.  

About GeneWize Life Sciences, Inc.:

GeneWize is a wholly owned subsidiary of GeneLink Biosciences and is the first network sales company to focus on providing individually customized nutritional and skin care formulations based on a consumer's personal DNA assessment.  The company's mission is to empower individuals to take personal responsibility and control of their health.  For additional information, please visit: www.genewize.com.

This release contains certain forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in the press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward-looking statement. GeneLink disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future developments or otherwise.

SOURCE GeneLink, Inc.

Back to top

RELATED LINKS
http://www.genelinkbio.com

'/>"/>

SOURCE GeneLink, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Forest Laboratories Announces Federal Appeals Court Upholds Lexapro(R) Patent Decision
2. XTL to Appeal NASDAQ Staff Determination; XTL May Transfer its ADR Listing to the NASDAQ Capital Market
3. Genta Completes Appeal of FDA Decision for Genasense(R) in CLL
4. Insmed to Appeal Delisting Notification From Nasdaq
5. Wyeth To Appeal Arkansas Hormone Therapy Trial Verdicts
6. WorldHeart Announces Delisting Appeal Received and Will be Considered at Hearing July 10, 2008
7. Ortho-McNeil Neurologics to Appeal Patent Ruling on RAZADYNE(R)
8. Court of Appeals Overturns 2005 Patent Verdict Against Cordis
9. Federal Circuit Rules in Marteks Favor in Appeal of Patent Infringement Case
10. Hertz Annual Appeal for Adult Congenital Heart Disease Center At UCLA Passes $2-Million Mark in Funds Raised Over Ten Years
11. Cell Therapeutics Wins Federal Appeal to Pursue $22.8 Million Claim Against The Lash Group
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... NY (PRWEB) , ... January 18, 2017 , ... Researchers from a new study ... do not fall low enough after prostate cancer treatment, this indicates there is still remaining ... risk of mortality. , “ The PSA test has always been an indicator of whether ...
(Date:1/18/2017)... , ... January 18, 2017 , ... Thirty-six startup companies ... credits by the Pennsylvania Department of Community and Economic Development in 2016 as part ... located in the University City Keystone Innovation Zone and represent the highest number of ...
(Date:1/18/2017)... , Jan. 18, 2017 /PRNewswire/ - SQI ... sciences and diagnostics company that develops and commercializes ... ("SQI" or the "Company"), today announced that ... Inc. ("Kingsdale"), has resigned from its Board of ... changes to securities regulations that have limited both ...
(Date:1/17/2017)... , Jan. 17, 2017 The Global ... a CAGR of around 7.5% over the next ... Some of the prominent trends that the market ... of diseases & graft transplant surgeries and medical ... the market is categorized into immunomodulatory biomaterials, natural, ...
Breaking Biology Technology:
(Date:12/15/2016)... Dec. 14, 2016 "Increase in mobile transactions ... The mobile biometrics market is expected to grow from ... by 2022, at a CAGR of 29.3% between 2016 ... as the growing demand for smart devices, government initiatives, ... "Software component is expected to grow at a ...
(Date:12/8/2016)...  Singulex, Inc., the leader in Next Generation Immunodiagnostics ... license and supply agreement with Thermo Fisher Scientific, the ... access to Thermo Scientific BRAHMS PCT (Procalcitonin), a biomarker ... to diagnose systemic bacterial infection and sepsis and in ... in assessing the risk of critically ill patients for ...
(Date:12/7/2016)... 7, 2016   Avanade is helping Williams ... teams in history, exploit biometric data in order to ... maintain the competitive edge against their rivals after their ... Avanade has worked with Williams during the 2016 ... data (heart rate, breathing rate, temperature and peak acceleration) ...
Breaking Biology News(10 mins):